Publications by authors named "K Mangoff"
SPiReL is a phase II clinical trial evaluating combination immunotherapy, pembrolizumab and cyclophosphamide, with maveropepimut-S, in survivin-expressing relapsed/refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL). We describe baseline tumor survivin expression and associations with clinico-pathological variables in 25 participants. The median number of survivin-expressing cells was 99%, and the intensity of survivin expression within tumors was heterogeneous by semi-quantitative immunohistochemistry assessment.
View Article and Find Full Text PDFBackground: Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options.
Methods: R/R DLBCL patients, who were mostly ineligible for ASCT due to age or comorbidities, were treated with maveropepimut-S (MVP-S, previously DPX-Survivac) a survivin directed T cell educating therapy, pembrolizumab, and intermittent low-dose cyclophosphamide.
Findings: We identified, using univariate analysis, a subset of patients with enhanced ORR, PFS and DOR.
Article Synopsis
- Metformin is commonly used during pregnancy in women with type 2 diabetes, but its long-term effects on children are still being studied, specifically regarding their body fat and growth patterns up to 24 months of age.
- The MiTy Kids follow-up study included 283 children and found no significant differences in average body mass index (BMI) or skinfold thickness between those exposed to metformin and those who received a placebo during pregnancy.
- Despite the overall similarity in growth trajectories, boys in the metformin group showed higher BMI rates between 6 and 24 months, indicating the need for further research on how metformin may affect male child development.
Objective: Does planned caesarean compared with planned vaginal birth lower the risk of problematic urinary stress, faecal, or flatal incontinence?
Design: Women between 32 and 38 weeks of gestation with a twin pregnancy were randomised to planned caesarean or planned vaginal birth.
Setting: The trial took place at 106 centres in 25 countries.
Population: A total of 2305 of the 2804 women enrolled in the study completed questionnaires at 2 years (82.